---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-035706"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:53:23.167158+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions closes $4.38M public offering, net proceeds ~$3.35M

## Summary
- Gross proceeds of $4.378M from offering of 2.23M common shares, 5.73M Series E preferred, and warrants to purchase up to 7.96M shares.
- Net proceeds of approximately $3.35M after underwriting discounts and expenses, for general corporate purposes and working capital.
- Series E Preferred Stock is convertible 1:1 into common stock, no dividend rights except as paid on common, limited voting rights.
- CFO Spiro Sakiris purchased 112,727 Class A Units and director Christopher Towers purchased 9,090 Class A Units on same terms.
- Underwriter's overallotment option partially exercised; warrants exercisable only after Nasdaq shareholder approval.

## SEC filing metadata
- accession: 0001493152-23-035706
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/0001493152-23-035706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-035706
- JSON: https://secwatch.observer/filing/0001493152-23-035706.json
- Plain text: https://secwatch.observer/filing/0001493152-23-035706.txt

## Key facts
- Governance Changes
  INTELLIGENT BIO SOLUTIONS INC.: Filed Certificate of Designation for Series E Convertible Preferred Stock, designating 5,728,723 shares of Series E Preferred Stock, with no voting rights, convertible into common stock, and no dividends unless declared by the board (effective 2023-10-03).
  - Change: charter amendment
  - Effective: 2023-10-03
  source text: In connection with the Public Offering, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware on October 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/0001493152-23-035706-index.htm
- Material Agreements
  INTELLIGENT BIO SOLUTIONS INC. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. (effective 2023-10-02).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Effective: 2023-10-02
  source text: On October 2, 2023, Intelligent Bio Solutions Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as representative (the “Representative”) of the underwriters named in Schedule I thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell, in a registered public offering by the Company (the “Public Offering”): (a) 1,544,004 Class A Units
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315223035706/0001493152-23-035706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.